Cannabidiol-Loaded Nanostructured Lipid Carriers (NLCs) for Dermal Delivery: Enhancement of Photostability, Cell Viability, and Anti-Inflammatory Activity

Morakul, Boontida; Junyaprasert, Varaporn Buraphacheep; Sakchaisri, Krisada; Teeranachaideekul, Veerawat

doi:10.3390/pharmaceutics15020537

Cited by 21 publications

(10 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No melting peak of CBD was observed for both CBD-NLCs and CBD film showing that either CBD has dissolved or in amorphous state. Similar finding was reported by Morakul and collegues [ 79 ]. Furthermore, the endothermic peak of Precirol ® ATO 5 was observed at 57.2 °C in lipid mix and pure Precirol ® ATO 5 [ 31 , 80 ].…”

Section: Resultssupporting

confidence: 92%

Combining the potential of 3D printed buccal films and nanostructured lipid carriers for personalised cannabidiol delivery

Abdella,

Kim,

Afinjuomo

et al. 2023

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Cannabidiol (CBD) has been recognized for its numerous therapeutic benefits, such as neuroprotection, anti-inflammatory effects, and cardioprotection. However, CBD has some limitations, including unpredictable pharmacokinetics and low oral bioavailability. To overcome the challenges associated with CBD delivery, we employed Design of Experiments (DoE), lipid carriers, and 3D printing techniques to optimize and develop buccal film loaded with CBD-NLCs. Three-factor Box-Behnken Design was carried out to optimise the NLCs and analyse the effect of independent factors on dependent factors. The emulsification-ultrasonication technique was used to prepare the NLCs. A pressure-assisted micro-syringe printing technique was used to produce the films. The produced films were studied for physicochemical, and mechanical properties, release profiles, and predicted in vivo performance. The observed particle size of the NLCs ranged from 12.17 to 84.91 nm whereas the PDI varied from 0.099 to 0.298. Lipid and sonication time positively affected the particle size whereas the surfactant concentration was inversely related. CBD was incorporated into the optimal formulation and the observed particle size, PDI, and zeta potential for the CBD-NLCs were 94.2 ± 0.47 nm, 0.11 ± 0.01 and − 11.8 ± 0.52 mV. Hydroxyethyl cellulose (HEC)-based gel containing the CBD-NLCs was prepared and used as a feed for 3D printing. The CBD-NLCs film demonstrated a slow and sustained in vitro release profile (84. 11 ± 7.02% in 6 h). The predicted AUC0–10 h, Cmax, and Tmax were 201.5 µg·h/L, 0.74 µg/L, and 1.28 h for a film with 0.4 mg of CBD, respectively. The finding demonstrates that a buccal film of CBD-NLCs can be fabricated using 3D printing. Graphical Abstract

show abstract

Section: Resultssupporting

confidence: 92%

Combining the potential of 3D printed buccal films and nanostructured lipid carriers for personalised cannabidiol delivery

Abdella,

Kim,

Afinjuomo

et al. 2023

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

show abstract

“…Similar nding was reported by Morakul and collegues 75 . Furthermore, the endothermic peak of GDS was observed at 57.2°C in lipid mix and pure GDS 30,76 .…”

Section: Dsc Studiessupporting

confidence: 91%

Harnessing the Synergistic Potential of 3D Printed Buccal Films and Nanostructured Lipid Carriers (NLCs) For Personalised Cannabidiol Delivery

Abdella

Kim

Afinjuomo

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Cannabidio(CBD) has been recognized for its numerous therapeutic benefits, such as neuroprotection, anti-inflammatory effects, and cardioprotection. However, CBD has some limitations, including unpredictable pharmacokinetics and low oral bioavailability. To overcome the challenges associated with CBD delivery, we employed Design of Experiments (DoE), lipid carriers, and 3D printing techniques to optimize and develop buccal film loaded with CBD-NLCs. Methods: Three-factor Box-Behnken Design was carried out to optimise the NLCs and analyse the effect of independent factors on dependent factors. The emulsification-ultrasonication technique was used to prepare the NLCs. A pressure-assisted micro-syringe printing technique was used to produce the films. The produced films were studied for physicochemical, and mechanical properties, release profiles, and predicted in vivo performance. Results: The observed particle size of the NLCs ranged from 12.17 to 84.91nm whereas the PDI varied from 0.099 to 0.298. Lipid and sonication time positively affected the particle size whereas the surfactant concentration was inversely related. CBD was incorporated into the optimal formulation and the observed particle size, PDI, and zeta potential for the CBD-NLCs were 94.2 ±0.47nm, 0.11± 0.01 and−11.8 ± 0.52 mV. Hydroxyethyl cellulose (HEC)-based gel containing the CBD-NLCs was prepared and used as a feed for 3D printing. The CBD-NLCs film demonstrated a two-phase in vitro release profile, wherein an initial burst release of 47% occurred within the first 2h. The predicted AUC0–10h, Cmax, and Tmax were 201.5µg·h/L, 0.74 µg/L, and 1.28 h for a film with 0.4 mg of CBD, respectively. Conclusion: The finding demonstrates that a buccal film of CBD-NLCs can be fabricated using 3D printing.

show abstract

“…[74][75][76][77] When compared to other nano formulation systems, such as transfersome, NLC and so on, CTD-12 still indicated higher performance. [78][79][80][81][82] Therefore, CTD-12 was chosen as a promising transdermal formulation for further prospective application use in transdermal drug patches.…”

Section: Resultsmentioning

confidence: 99%

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Chu,

Liao,

Liu

et al. 2024

IJN

View full text Add to dashboard Cite

Purpose: Cannabidiol (CBD) is a promising therapeutic drug with low addictive potential and a favorable safety profile. However, CBD did face certain challenges, including poor solubility in water and low oral bioavailability. To harness the potential of CBD by combining it with a transdermal drug delivery system (TDDS). This innovative approach sought to develop a transdermal patch dosage form with micellar vesicular nanocarriers to enhance the bioavailability of CBD, leading to improved therapeutic outcomes. Methods: A skin-penetrating micellar vesicular nanocarriers, prepared using nano emulsion method, cannabidiol loaded transdermal nanocarriers-12 (CTD-12) was presented with a small particle size, high encapsulation efficiency, and a drug-loaded ratio for CBD. The skin permeation ability used Strat-M™ membrane with a transdermal diffusion system to evaluate the CTD and patch of CTD-12 (PCTD-12) within 24 hrs. PCTD-12 was used in a preliminary pharmacokinetic study in rats to demonstrate the potential of the developed transdermal nanocarrier drug patch for future applications. Results: In the transdermal application of CTD-12, the relative bioavailability of the formulation was 3.68 ± 0.17-fold greater than in the free CBD application. Moreover, PCTD-12 indicated 2.46 ± 0.18-fold higher relative bioavailability comparing with free CBD patch in the ex vivo evaluation. Most importantly, in the pharmacokinetics of PCTD-12, the relative bioavailability of PCTD-12 was 9.47 ± 0.88-fold higher than in the oral application. Conclusion: CTD-12, a transdermal nanocarrier, represents a promising approach for CBD delivery, suggesting its potential as an effective transdermal dosage form.

show abstract

Cannabidiol-Loaded Nanostructured Lipid Carriers (NLCs) for Dermal Delivery: Enhancement of Photostability, Cell Viability, and Anti-Inflammatory Activity

Cited by 21 publications

References 56 publications

Combining the potential of 3D printed buccal films and nanostructured lipid carriers for personalised cannabidiol delivery

Combining the potential of 3D printed buccal films and nanostructured lipid carriers for personalised cannabidiol delivery

Harnessing the Synergistic Potential of 3D Printed Buccal Films and Nanostructured Lipid Carriers (NLCs) For Personalised Cannabidiol Delivery

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Contact Info

Product

Resources

About